Ngā hua rapu - Ribera, E

5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) mā Lazzarin, A, Johnson, M, Ribera, E, Weitner, L, Chen, SS, Warren, DR

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Adenosine deaminase activity in the diagnosis of tuberculous peritonitis. mā Martinez-Vazquez, J M, Ocaña, I, Ribera, E, Segura, R M, Pascual, C

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Adenosine deaminase activity in tuberculous pericarditis. mā Martinez-Vazquez, J M, Ribera, E, Ocaña, I, Segura, R M, Serrat, R, Sagrista, J

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Adenosine deaminase activity in rheumatoid pleural effusion. mā Ocaña, I, Ribera, E, Martinez-Vázquez, J M, Ruiz, I, Bejarano, E, Pigrau, C, Pahissa, A

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients. mā Gómez-Jiménez, J, Ribera, E, Gasser, I, Artaza, M A, Del Valle, O, Pahissa, A, Martínez-Vázquez, J M

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice mā Llibre, JM, Martínez, E, Barreiro, P, Escrig, R, Ribera, E, Cervantes, M, Imaz, A, Gutierrez, F, Knobel, H, Ornelas, A, Zamora, FX, Clotet, B

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

¿Adelantan el diagnóstico de la diabetes tipo 2 los nuevos criterios de la Asociación Americana de Diabetes? mā Mata Cases, M., Cos Claramunt, X., Pujol Ribera, E., Bobé Molina, I., Centelles Fernández, R., Ortiz López, R., Ramos Fuertes, A., Royo Pastor, C.

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Diabetes mellitus tipo 2: incidencia y diagnóstico en un centro de atención primaria mā Mata Cases, M., Cos Claramunt, X., Bobé Molina, I., Pujol Ribera, E., Royo Pastor, C., Centelles Fernández, R., Davins Miralles, J., Ferrer-Vidal Cortella, D., Ortiz López, R.

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL mā Casado, JL, Domingo, P, Rubio, R, Antela, A, Lopez-Ruz, MA, Castro, A, Portilla, J, Ribera, E, Podzamczer, D, Oteo, JA, Galindo, J, Otero, S, Lozano, F, Estrada, V, Moltó, J, Moreno, S

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study mā Martínez, E, Arranz, JA, Podzamczer, D, Lonca, M, Sanz, J, Barragán, P, Knobel, H, Ribera, E, Gutierrez, F, Valero, S, Clotet, B, Dalmau, D, Segura, F, Arribas, JR, Barrufet, P, Santos, I, Payeras, A, de Lazzari, E, Pich, J, Gatell, J

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

CD4 response, lipid changes and liver outcome in 506 patients receiving nevirapine-based regimens for a median of 9 years mā Podzamczer, D, Tiraboschi, JM, Mallolas, J, Cárdenes, MA, Casas, E, Castro, A, Echevarria, S, Leal, M, Bernanldo de Quirós, JC Lopez, Moreno, S, Puig, T, Ribera, E, Villalonga, C, Gomez Sirvent, JL, Garcia Heranejos, JA, Lopez-Aldeguer, J, Barrufet, P, Force, L, Santos, I, Sanz, J

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study... mā Podzamczer, D, Micán, R, Tiraboschi, J, Portilla, J, Domingo, P, Llibre, J M, Ribera, E, Vivancos, M J, Morano, L, Masiá, M, Gómez, C, Fanjul, F, Payeras, A, Inciarte, A, Estrada, V, Rivero, A, Castro, Á, Bernal, E, Vinuesa, D, Knobel, H, Troya, J, Macías, J, Montero, M, Sanz, J, Navarro-Alcaraz, A, Caicedo, A, Fernández, G, Martínez, E, Moreno, S

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa